Privium Fund Management B.V. Grows Stock Position in BioNTech SE Sponsored ADR $BNTX

Key Points

• Privium Fund Management B.V. boosted its BioNTech stake by 75.3% in Q4 to 33,300 shares (worth about $3.17M), making the stock its 27th largest holding and ~0.6% of the fund.
• BioNTech announced up to a $1 billion share buyback while reporting Q1 EPS that beat expectations but a large revenue miss and updated 2026 guidance, and plans to close sites and cut about 1,860 jobs, signaling near‑term execution risk.
• COO Sierk Poetting sold 50,000 shares for roughly $5.53M under a Rule 10b5‑1 plan (an 11.13% reduction in his stake); corporate insiders now own about 19.2% of the company.

Privium Fund Management B.V. boosted its position in BioNTech SE Sponsored ADR (NASDAQ:BNTX - Free Report) by 75.3% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 33,300 shares of the company's stock after buying an additional 14,300 shares during the quarter. BioNTech makes up about 0.6% of Privium Fund Management B.V.'s holdings, making the stock its 27th largest position. Privium Fund Management B.V.'s holdings in BioNTech were worth $3,170,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. Huntington National Bank increased its position in BioNTech by 1,266.7% in the third quarter. Huntington National Bank now owns 410 shares of the company's stock worth $40,000 after buying an additional 380 shares during the last quarter. Tower Research Capital LLC TRC increased its position in BioNTech by 118.2% in the second quarter. Tower Research Capital LLC TRC now owns 563 shares of the company's stock worth $60,000 after buying an additional 305 shares during the last quarter. Rakuten Securities Inc. increased its position in BioNTech by 188.1% in the third quarter. Rakuten Securities Inc. now owns 1,043 shares of the company's stock worth $103,000 after buying an additional 681 shares during the last quarter. Hantz Financial Services Inc. increased its position in BioNTech by 100.3% in the third quarter. Hantz Financial Services Inc. now owns 1,146 shares of the company's stock worth $113,000 after buying an additional 574 shares during the last quarter. Finally, Jones Financial Companies Lllp increased its position in BioNTech by 50.6% in the third quarter. Jones Financial Companies Lllp now owns 1,199 shares of the company's stock worth $118,000 after buying an additional 403 shares during the last quarter. 15.52% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the company. BMO Capital Markets reduced their price target on BioNTech from $143.00 to $128.00 and set an "outperform" rating for the company in a research report on Wednesday, March 11th. Berenberg Bank reiterated a "buy" rating on shares of BioNTech in a research report on Monday, April 13th. Truist Financial upgraded BioNTech to a "strong-buy" rating in a research report on Wednesday, March 25th. Leerink Partners cut BioNTech from an "outperform" rating to a "market perform" rating and set a $113.00 price target for the company. in a research report on Monday, February 2nd. Finally, Bank of America reiterated a "buy" rating and issued a $128.00 price target on shares of BioNTech in a research report on Tuesday, March 10th. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, BioNTech has a consensus rating of "Moderate Buy" and a consensus target price of $133.13.

Insider Transactions at BioNTech

In related news, COO Sierk Poetting sold 50,000 shares of BioNTech stock in a transaction on Wednesday, April 22nd. The stock was sold at an average price of $110.56, for a total transaction of $5,528,000.00. Following the completion of the sale, the chief operating officer owned 399,387 shares of the company's stock, valued at approximately $44,156,226.72. This trade represents a 11.13% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 19.20% of the company's stock.

Key BioNTech News

Here are the key news stories impacting BioNTech this week:

• Positive Sentiment: Company authorized a share buyback program of up to $1 billion, which supports capital return and offsets some sell-side pressure. BioNTech to close sites in Germany, Singapore affecting 1,860 staff
• Positive Sentiment: Reported Q1 EPS (loss) of ($2.26) but it beat consensus loss expectations, which may ease some near-term investor concern about profitability dynamics. BioNTech Q1 results (MarketBeat)
• Neutral Sentiment: Full-year 2026 revenue guidance was updated to a $2.3B–$2.7B range (consensus ~ $2.6B), leaving headline guidance roughly in line with expectations but with a wide band that signals execution risk. BioNTech Announces First-Quarter 2026 Financial Results and Corporate Update
• Neutral Sentiment: Management held its Q1 earnings call and the full transcript/slides are available for investors to review details on guidance, cost savings and pipeline priorities. BioNTech Q1 2026 Earnings Call Transcript
• Negative Sentiment: Revenue missed estimates: Q1 sales were $136.6M vs. consensus ~$207.4M, a ~35% YoY decline driven by lower COVID‑vaccine demand — the primary near-term growth driver — which pressured the share price. BioNTech Slides As Vaccine Sales Drop, Restructuring Plan Takes Shape
• Negative Sentiment: Company will close manufacturing sites (including assets from the CureVac deal) and cut up to ~1,860 jobs as part of a restructuring to reduce costs — a sizeable one-time disruption that signals weaker demand and creates near-term execution risk; two co‑founders also resigned. BioNTech to Close Sites, Cut Quarter of Workforce in Savings Push

BioNTech Price Performance

Shares of NASDAQ BNTX opened at $95.50 on Wednesday. The stock has a market cap of $24.15 billion, a PE ratio of -18.23 and a beta of 1.36. BioNTech SE Sponsored ADR has a fifty-two week low of $79.52 and a fifty-two week high of $124.00. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.49 and a current ratio of 7.54. The stock has a fifty day moving average of $97.23 and a 200-day moving average of $101.06.

BioNTech (NASDAQ:BNTX - Get Free Report) last posted its quarterly earnings data on Saturday, February 14th. The company reported ($0.39) earnings per share (EPS) for the quarter. The business had revenue of $1.06 billion for the quarter. BioNTech had a negative net margin of 38.09% and a negative return on equity of 4.76%. Equities research analysts anticipate that BioNTech SE Sponsored ADR will post -4.55 earnings per share for the current year.

BioNTech Profile

BioNTech SE NASDAQ: BNTX is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech's core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.